The Absorb GT1 Bioresorbable Vascular Scaffold System　― 5-Year Post-Market Surveillance Study in Japan ―-Reference-Cited by-同舟云学术

The Absorb GT1 Bioresorbable Vascular Scaffold System　― 5-Year Post-Market Surveillance Study in Japan ―

Published:2024-05-24 Issue:6 Volume:88 Page:863-872
ISSN:1346-9843
Container-title:Circulation Journal
language:en
Short-container-title:Circ J

Author:

Nakamura Masato¹,Suzuki Nobuaki²,Fujii Kenshi³,Furuya Jungo⁴,Kawasaki Tomohiro⁵,Kimura Takumi⁶,Sakamoto Tomohiro⁷,Tanabe Kengo⁸,Kusano Hajime⁹,Stockelman Kelly A.⁹,Kozuma Ken¹⁰

Affiliation:

1. Division of Minimally Invasive Treatment in Cardiovascular Medicine, Toho University Ohashi Medical Center

2. Fourth Department of Internal Medicine, Teikyo University School of Medicine

3. Department of Cardiovascular Medicine, Sakurabashi Watanabe Hospital

4. Department of Cardiovascular Medicine, Hanaoka Seishu Memorial Hospital

5. Department of Cardiovascular Medicine, Shin Koga Hospital

6. Department of Cardiovascular Medicine, Iwate Medical University Hospital

7. Department of Cardiovascular Medicine, Saiseikai Kumanoto Hospital

8. Division of Cardiology, Mitsui Memorial Hospital

9. Abbott Vascular

10. Department of Cardiovascular Medicine, Teikyo University Hospital

Publisher

Japanese Circulation Society

Link

https://www.jstage.jst.go.jp/article/circj/88/6/88_CJ-23-0877/_pdf

Reference34 articles.

1. 1. Bangalore S, Kumar S, Fusaro M, Amoroso N, Attubato MJ, Feit F, et al. Short- and long-term outcomes with drug-eluting and bare-metal coronary stents: A mixed-treatment comparison analysis of 117 762 patient-years of follow-up from randomized trials. Circulation 2012; 125: 2873–2891, doi:10.1161/CIRCULATIONAHA.112.097014.

2. 2. Madhavan MV, Kirtane AJ, Redfors B, Généreux P, Ben-Yehuda O, Palmerini T, et al. Stent-related adverse events >1 year after percutaneous coronary intervention. J Am Coll Cardiol 2020; 75: 590–604, doi:10.1016/j.jacc.2019.11.058.

3. 3. Iqbal J, Serruys PW, Silber S, Kelbaek H, Richardt G, Morel MA, et al. Comparison of zotarolimus- and everolimus-eluting coronary stents: Final 5-year report of the RESOLUTE all-comers trial. Circ Cardiovasc Interv 2015; 8: e002230, doi:10.1161/CIRCINTERVENTIONS.114.002230.

4. 4. Jeong YJ, Ahn JM, Hyun J, Lee J, Kim JH, Yang Y, et al. Ten-year outcomes after drug-eluting stents or bypass surgery for left main coronary disease in patients with and without diabetes mellitus: The PRECOMBAT extended follow-up study. J Am Heart Assoc 2021; 10: e019834, doi:10.1161/JAHA.120.019834.

5. 5. Brodie B, Pokharel Y, Fleishman N, Bensimhon A, Kissling G, Hansen C, et al. Very late stent thrombosis after primary percutaneous coronary intervention with bare-metal and drug-eluting stents for ST-segment elevation myocardial infarction: A 15-year single-center experience. JACC Cardiovasc Interv 2011; 4: 30–38, doi:10.1016/j.jcin.2010.11.004.

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Bioresorbable Scaffolds　― A Ray of Hope in the Darkness ―;Circulation Journal;2024-05-24